


228.1010

Applicants believe that claims, as presented, are in condition for allowance. An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

International PCT Application No. PCT/EP00/03612

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims have been amended as follows:

3. (Amended) Method according to claim 1 [or claim 2] , characterized in that, the matrix is amorphous or partially amorphous.
4. (Amended) Method according claim 1 [to any one of the preceeding claims] , characterized in that, the polysaccharide is starch or a derivative thereof.
5. (Amended) Method according claim 1 [to any one of the preceding claims], characterized in that, the matrix is water-soluble.
6. (Amended) Method according to claim 1 [according to any one of the preceding claims] , characterized in that, the matrix is a controlled release matrix.
7. (Amended) Method according to claim 1 [any one of the preceding claims], characterized in that, the release of the active agent of the dosage form substantially follows the lapidus function.
8. (Amended) Method according to claim 1 [any one of the preceding claims], characterized in that, the release of the active agent of the dosage form may be adjusted over 24 hours or more.
9. (Amended) Method according to claim 1 [any one of the preceding claims], characterized in that, at least one pharmaceutically active agent is present in the matrix in dissolved, solid or liquid form.

228.1010

12. (Amended) Dosage form according to claim 10 [or claim 11], characterized in that, the matrix is amorphous or partially amorphous.
13. (Amended) Dosage form according to claim 10 [any one of claims 10 to 12], characterized in that, the polysaccharide is starch or a derivative thereof.
14. (Amended) Dosage form according to claim 10 [any one of claims 10 to 13], characterized in that, the matrix is water-insoluble.
15. (Amended) Dosage form according to claim 10 [any one of claims 10 to 14] , characterized in that, the matrix is a controlled release matrix.
16. (Amended) Dosage form according to claim 10 [any one of claims 10 to 15], characterized in that, the release of the active agent substantially follows the lapidus function.
17. (Amended) Dosage form according to claim 10 [any one of claims 10 to 16], characterized in that, the release of the active agent is adjusted over a period of up to 24 hours or longer.
18. (Amended) Dosage form according to claim 10 [any one of claims 10 to 17], characterized in that, at least one pharmaceutically active agent is present in the matrix in dissolved, solid or liquid form.
19. (Amended) Use of a dosage form according to claim 10 [to 18] for producing granulates for tableting the filling capsules, for further processing using injection molding techniques, as an adjuvant for direct tableting and/or for producing mono-block pharmaceutical dosage forms.